The 2022 OncoAlert Colloquium Day 2: GU Oncology

The 2022 OncoAlert Colloquium Day 1: Breast Cancer

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1

ASH 2022: Multiple myeloma roundup

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML

Comment: POLAR gene profile can identify which patients can safely avoid radiation therapy after breast-conserving surgery

Updates from TAILORx and RxPONDER: Implications for practice

Maximising cancer treatment and research through omics, data sharing, and open science

What is required to advance data ethics, data sharing, and Open Science across LMICs

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC

Cloud software for helping build quality assurance in radiotherapy

Strategic Training Achievements for Research Success (STARS): Increasing cancer research capacity in Africa